Filing Details

Accession Number:
0000950103-25-003297
Form Type:
13D Filing
Publication Date:
2025-03-11 20:00:00
Filed By:
ASE Technology Holding Co., Ltd.
Company:
Ainos Inc.
Filing Date:
2025-03-12
SEC Url:
13D Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
ASE Technology Holding Co., Ltd. 0 3,148,788 0 3,148,788 3,148,788 17.0%
ASE Test, Inc. ("ASE Test Taiwan") 0 3,148,788 0 3,148,788 3,148,788 17.0%
Filing





If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D



Comment for Type of Reporting Person:
Note to Rows 8, 10, and 11: Represents beneficial ownership of 3,148,788 shares of Common Stock, $0.01 par value (the "Common Stock"), of Ainos, Inc., a Texas corporation (the "Issuer") consisting of the following: (i) 29,411 shares owned directly by ASE Test Taiwan (as defined below); (ii) 499,377 shares pursuant to the 2023 Agreement (as defined below) between ASE Test Taiwan and the Issuer, as amended by the 2023 Agreement Amendment (as defined below); (iii) 2,120,000 shares of common stock pursuant to the 2024 Agreement (as defined below) between ASE Test Taiwan and the Issuer; and (iv) 500,000 shares that ASE Test Taiwan can obtain by conversion of a warrant it holds that was issued under the 2024 Agreement. For the purposes of these calculations, the number of shares convertible under the 2023 Agreement, as amended by the 2023 Agreement Amendment, is calculated based on a conversion price of $4.50 per share. This conversion price represents the maximum potential number of shares ASE Test Taiwan could receive upon conversion. For further details, please see Item 3 and Item 6. Note to Row 13: Based on the sum of (i) 15,433,257 shares of common stock outstanding as of March 7, 2025 as set forth in the annual report on Form 10-K of the Issuer filed with the SEC on March 7, 2025 (ii) 499,377 shares of common stock convertible pursuant to the 2023 Agreement (as defined below) as amended and modified by the 2023 Agreement Amendment (as defined below) (iii) 2,120,000 shares of common stock convertible pursuant to the 2024 Agreement (as defined below) and (iv) 500,000 shares of common stock convertible upon the exercise of the warrant ASE Test Taiwan obtained as part of the 2024 Agreement.


SCHEDULE 13D



Comment for Type of Reporting Person:
Note to Rows 8, 10, and 11: Represents beneficial ownership of 3,148,788 shares of Common Stock, $0.01 par value (the "Common Stock"), of Ainos, Inc., a Texas corporation (the "Issuer") consisting of the following: (i) 29,411 shares owned directly by ASE Test Taiwan (as defined below); (ii) 499,377 shares pursuant to the 2023 Agreement (as defined below) between ASE Test Taiwan and the Issuer, as amended by the 2023 Agreement Amendment (as defined below); (iii) 2,120,000 shares of common stock pursuant to the 2024 Agreement (as defined below) between ASE Test Taiwan and the Issuer; and (iv) 500,000 shares that ASE Test Taiwan can obtain by conversion of a warrant it holds that was issued under the 2024 Agreement. For the purposes of these calculations, the number of shares convertible under the 2023 Agreement, as amended by the 2023 Agreement Amendment, is calculated based on a conversion price of $4.50 per share. This conversion price represents the maximum potential number of shares ASE Test Taiwan could receive upon conversion. For further details, please see Item 3 and Item 6. Note to Row 13: Based on the sum of (i) 15,433,257 shares of common stock outstanding as of March 7, 2025 as set forth in the annual report on Form 10-K of the Issuer filed with the SEC on March 7, 2025 (ii) 499,377 shares of common stock convertible pursuant to the 2023 Agreement (as defined below) as amended and modified by the 2023 Agreement Amendment (as defined below) (iii) 2,120,000 shares of common stock convertible pursuant to the 2024 Agreement (as defined below) and (iv) 500,000 shares of common stock convertible upon the exercise of the warrant ASE Test Taiwan obtained as part of the 2024 Agreement.


SCHEDULE 13D

 
ASE Technology Holding Co., Ltd.
 
Signature:/s/ Joseph Tung
Name/Title:Joseph Tung/ Chief Financial Officer
Date:03/12/2025
 
ASE Test, Inc. ("ASE Test Taiwan")
 
Signature:/s/ Alan Li
Name/Title:Alan Li/ Director
Date:03/12/2025